FDA gives expedited approval to new groundbreaking pancreatic cancer drug

The FDA has approved a revolutionary new pill, daraxonrasib, marking the first treatment of its kind for the most prevalent form of pancreatic cancer. The drug targets a specific mutated protein responsible for driving tumor growth in over 90% of cases, a breakthrough that pharmaceutical companies have struggled to achieve for years. This expedited approval offers patients a potential new weapon against one of the deadliest cancers. The treatment represents a major shift in how pancreatic cancer may be managed in the future.

FDA officials approve first-of-a-kind pill called daraxonrasib to fight one of the deadliest types of cancerThe US Food and Drug Administration (FDA) approved a groundbreaking new drug for the most common form of pancreatic cancer, offering US patients a more effective treatment against one of the deadliest types of the disease.FDA officials gave expedited approval to the first-of-a-kind pill, called daraxonrasib, that blocks a mutated protein which fuels tumor growth in more than 90% of pancreatic cancer cases. It’s an approach that has eluded drugmakers for decades. Continue reading...